Clinical trial
A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- April 22, 2024
- Completion date
- July 30, 2027
- Enrollment
- 111 (actual)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.